Table 1.
Patients’ characteristics and clinicopathological data of subjects involved in the study
| Characteristics | PCa (n=64) | BPH (n=79) |
|---|---|---|
| Mean age (range), years | 63 (53–66) | 59 (53–65) |
| Mean PSA (range), ng/mL | 5.50 (3.20–9.3) | 4.85 (2.59–8.6) |
| Clinical stage, n (%) | ||
| T1c | 40 (62.5) | |
| T2a | 4 (6.2) | |
| T2b | 8 (12.5) | |
| T2c | 12 (18.8) | |
| Pathological Gleason score | ||
| 6 (3+3) | 35 | |
| 7 (3+4) | 16 | |
| 7 (4+3) | 9 | |
| 8 (4+4) | 4 | |
| Lymph node involvement, n (%) | 8 (12.5) | |
| Pathological stage, n (%) | ||
| T2a | 28 (43.75) | |
| T2b | 18 (28.12) | |
| T2c | 16 (25) | |
| T3a | 2 (3.13) | |
| EAU risk groups for biochemical recurrence of localized and locally advanced PCa | ||
| Low risk | N=28 | |
| Intermediate risk | N=18 | |
| High risk | N=18 | |
Abbreviations: BPH, benign prostatic hyperplasia; EAU, European Association of Urology; PCa, prostate cancer; PSA, prostate specific antigen.